19F and 1H MRI detection of amyloid β plaques in vivo
19F and 1H MRI detection of amyloid β plaques in vivo
复制标题
DOI：
10.1038/nn1422
复制
发表时间：
2005-04-01
影响因子：
25
通讯作者：
Saido, TC
中科院分区：
文献类型：
--
作者：
Higuchi, M;Iwata, N;Saido, TC
由淀粉样β肽组成的老年斑的形成，是阿尔茨海默病的病理标志，在人脑中先于疾病发作多年。此类斑块的非侵入性检测对于症状前诊断至关重要，并有助于早期预防性治疗策略。使用淀粉样蛋白前体蛋白（APP）转基因小鼠作为淀粉样蛋白β淀粉样变性的模型，我们在这里证明，静脉注射F-19-含有淀粉样蛋白的化合物标记脑斑块，并允许它们在活体小鼠中通过磁共振成像（MRI）使用F-19和H-1可视化。我们的发现为特异性非侵入性淀粉样蛋白成像提供了一个新的方向，而没有暴露于辐射的危险。这种方法可用于阿尔茨海默病小鼠模型的纵向研究，以寻找与淀粉样蛋白β病理学相关的生物标志物，并在候选药物治疗后跟踪疾病进程。
Formation of senile plaques composed of amyloid beta peptide, a pathological hallmark of Alzheimer disease, in human brains precedes disease onset by many years. Noninvasive detection of such plaques could be critical in presymptomatic diagnosis and could contribute to early preventive treatment strategies. Using amyloid precursor protein (APP) transgenic mice as a model of amyloid beta amyloidosis, we demonstrate here that an intravenously administered F-19-containing amyloidophilic compound labels brain plaques and allows them to be visualized in living mice by magnetic resonance imaging ( MRI) using F-19 and H-1. Our findings provide a new direction for specific noninvasive amyloid imaging without the danger of exposure to radiation. This approach could be used in longitudinal studies in mouse models of Alzheimer disease to search for biomarkers associated with amyloid beta pathology as well as to track disease course after treatment with candidate medications.